Kairuide Pharmaceutical

Mabwell (Shanghai) Bioscience is a leading clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutic antibodies and antibody-drug conjugates (ADCs). Often identified by its prominent research subsidiary, Kairuide Pharmaceutical, the company has established a deep and diversified pipeline of over 10 clinical-stage assets targeting oncology, autoimmune, and metabolic diseases. Key programs include MIL62, a next-generation ADCC-enhanced anti-CD20 antibody currently under NDA review in China, and 9MW2821, a Nectin-4 targeted ADC that has reached Phase 3 trials for urothelial carcinoma. Mabwell utilizes several proprietary technology platforms for antibody discovery and site-specific ADC conjugation to address unmet medical needs. The company operates a full-value-chain model, possessing comprehensive capabilities ranging from early-stage research to large-scale commercial manufacturing.